Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Полное описание

Библиографические подробности

Главные авторы:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2017-06-01
Серии:	Blood Advances
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!